Regulated information

ANNUAL RESULTS 2022 (slideshow)

01.2022 Highlights
02.2022 Consolidated financial statements
03.Strategy and outlook

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Serving animal Health - 90 years

Serving animal Health for over 90 years

Monthly information regarding the total number of voting rights - February 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the « Reglement Général de L’Autorité des Marchés Financiers »

Buyback programs - February 2023

Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights - January 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Buyback programs - January 2023

Monthly communication regarding buyback programs 

In 2023 Vetoquinol celebrates its 90th anniversary. - 90 years

The story of an incredible family saga. From a regional pharmaceutical laboratory to a world leader in animal health.

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

CALENDAR 2023 Stock exchange market – non authorized periods

The "negative windows" are the abstention periods during which it is forbidden to trade in the Company's securities.